News Column

Study Findings from Iuliu Hatieganu University of Medicine and Pharmacy Broaden Understanding of Oncology Research (Repositioning metformin in...

July 15, 2014



Study Findings from Iuliu Hatieganu University of Medicine and Pharmacy Broaden Understanding of Oncology Research (Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery)

By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology. According to news reporting originating from Cluj Napoca, Romania, by NewsRx correspondents, research stated, "After sitting many years on the shelves of drug stores as a harmless antidiabetic drug, metformin comes back in the spotlight of the scientific community as a surprisingly effective antineoplastic drug. Metformin targets multiple pathways that play pivotal roles in cancer progression, impacting various cellular processes, such as proliferation, cell death, metabolism, and even the cancer stemness features."

Our news editors obtained a quote from the research from the Iuliu Hatieganu University of Medicine and Pharmacy, "The biomolecular characteristics of tumors, such as appropriate expression of organic cation transporters or genetic alterations including p53, K-ras, LKB1, and PI3K may impact metformin's anticancer efficiency. This could indicate a need for tumor genetic profiling in order to identify patients most likely to benefit from metformin treatment."

According to the news editors, the research concluded: "Considering that the majority of experimental models suggest that higher, supra-clinical doses of metformin should be used in order to obtain an antineoplastic effect, new ways of drug delivery could be developed, such as metformin-loaded nanoparticles or incorporation of metformin into microparticles used in transarterial chemoembolization, with the aim of obtaining higher intratumoral drug concentrations and a targeted therapy which will ultimately maximize metformin's efficacy."

For more information on this research see: Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery. Tumor Biology, 2014;35(6):5101-5110. Tumor Biology can be contacted at: Springer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands. (Springer - www.springer.com; Tumor Biology - www.springerlink.com/content/1010-4283/)

The news editors report that additional information may be obtained by contacting M. Aldea, Iuliu Hatieganu University of Medicine & Pharmacy, Dept. of Morphol Sci, Cluj Napoca 400337, Cluj, Romania. Additional authors for this research include L. Craciun, C. Tomuleasa, I. Berindan-Neagoe, G. Kacso, I.S. Florian and C. Crivii (see also Oncology).

Keywords for this news article include: Europe, Cancer, Romania, Genetics, Oncology, Cluj Napoca

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters